Quarterly ResultMay 4, 2026, 04:14 PM
BioMarin Q1 Revenue $766M; Raises FY26 Revenue Guidance to $3.825B-$3.925B
AI Summary
BioMarin Pharmaceutical Inc. reported first-quarter 2026 financial results, with total revenues increasing 3% year-over-year to $766 million. Despite a 43% decrease in GAAP Net Income to $106 million ($0.54 Diluted EPS) due to acquisition-related costs and a manufacturing charge, the company raised its full-year 2026 Total Revenues guidance to between $3.825 billion and $3.925 billion, reflecting accelerated growth from the recently completed Amicus Therapeutics acquisition. The acquisition adds GALAFOLD and POMBILITI + OPFOLDA to BioMarin's portfolio, though it is expected to be slightly dilutive to full-year Non-GAAP Diluted EPS, which was updated to $4.85 - $5.05.
Key Highlights
- Completed Amicus Therapeutics acquisition, adding GALAFOLD and POMBILITI + OPFOLDA to portfolio.
- Raised full-year 2026 Total Revenues guidance to $3.825 billion - $3.925 billion.
- Reported Q1 2026 Total Revenues of $766 million, a 3% increase year-over-year.
- Q1 2026 GAAP Net Income decreased 43% to $106 million, with Diluted EPS of $0.54.
- Updated full-year 2026 Non-GAAP Diluted EPS guidance to $4.85 - $5.05.
- Q1 Enzyme Therapies revenue grew 6% to $514 million; VOXZOGO revenue increased 3% to $220 million.
- Generated $221 million in operating cash flows during the first quarter.
- Secured approximately $3.7 billion in non-convertible debt to support the Amicus acquisition.